Trials have shown that semaglutide can reduce major cardiovascular events, but the extent of tirzepatide’s heart protection ...

Fact checked by Nick Blackmer People may react differently to GLP-1s due to factors like age, sex, and diet.  Side effects, such as nausea and vomiting, are common with both semaglutide and ...

Tirzepatide and semaglutide, while effective, are not cost-effective due to high prices, negating healthcare savings. Combining antiobesity medications with lifestyle modification improves health ...

Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.

Among people with obesity or overweight, tirzepatide users lost 20.2% of body weight compared with a 13.7% loss with semaglutide over 72 weeks. Participants on tirzepatide also lost 5.4 cm more in ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes. SAN FRANCISCO — By exceeding both standard and intensive ...

No significant increase in hazard ratios seen for GI events for semaglutide vs dulaglutide, tirzepatide vs dulaglutide, tirzepatide vs semaglutide. HealthDay News For patients with type 2 diabetes ...

Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

Use of semaglutide and tirzepatide, compared with sitagliptin, were associated with lower risks for heart failure hospitalization and mortality in HFpEF and type 2 diabetes. Use of semaglutide and ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...